1
98
J.L. Thomas et al. / Journal of Steroid Biochemistry & Molecular Biology 120 (2010) 192–199
is expressed in mammary gland, breast tumors, placenta and
References
skin, while 3-HSD2 is expressed in the adrenal gland and ovary
[
[
[
[
1] E. Rheaume, Y. Lachance, H.-F. Zhao, N. Breton, M. Dumont, Y. de Launoit, C.
Trudel, V. Luu-The, J. Simard, F. Labrie, Structure and expression of a new
complementary DNA encoding the almost exclusive 3 beta-hydroxysteroid
dehydrogenase/delta 5-delta 4-isomerase in human adrenals and gonads, Mol.
Endocrinol. 5 (8) (1991) 1147–1157.
2] B. Persson, Y. Kallberg, J.E. Bray, E. Bruford, S.L. Dellaporta, A.D. Favia, R.G.
Duarte, H. Jörnvall, K.L. Kavanagh, N. Kedishvili, M. Kisiela, E. Maser, R. Mind-
nich, S. Orchard, T.M. Penning, J.M. Thornton, J. Adamski, U. Oppermann, The
SDR (short-chain dehydrogenase/reductase and related enzymes) nomencla-
ture initiative, Chem. Biol. Interact. 178 (1–3) (2009) 94–98.
[
23]. Because the inhibition of adrenal 3-HSD2 may decrease
the production of cortisol and aldosterone in postmenopausal
women, inhibition of 3-HSD1 in breast tumors to block estra-
diol production could produce undesirable side effects. However,
we have shown that the classic 3-HSD inhibitors, trilostane and
epostane, competitively inhibit purified human 3-HSD1 with
1
2–16-fold higher affinity compared to the noncompetitive inhi-
bition of human 3-HSD2 by these compounds [12,24]. This study
identifies an amino acid in the steroid binding domain of human
3] J.L. Thomas, R.P. Myers, R.C. Strickler, Human placental 3-hydroxy-5-ene-
steroid dehydrogenase and steroid 5-4-ene-isomerase: purification from
mitochondria and kinetic profiles, biophysical characterization of the puri-
fied mitochondrial and microsomal enzymes, J. Steroid Biochem. 33 (2) (1989)
3
-HSD1 that may be exploited to produce new inhibitors that are
much more highly specific for 3-HSD1 in breast tumors compared
to adrenal 3-HSD2, so the side effect of adrenal insufficiency may
be avoided.
209–217.
4] S. Gingras, R. Moriggl, B. Groner, J. Simard, Induction of 3beta-hydroxysteroid
dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human
breast cancer cell lines and in normal mammary epithelial cells by interleukin-4
and interleukin-13, Mol. Endocrinol. 13 (1) (1999) 66–81.
5] W.E. Rainey, B.R. Carr, H. Sasano, T. Suzuki, J.I. Mason, Dissecting human adrenal
androgen production, Trends Endocrinol. Metab. 13 (6) (2002) 234–239.
6] J.L. Thomas, J.I. Mason, S. Brandt, B.R. Spencer, W. Norris, Structure/function
relationships responsible for the kinetic differences between human type 1
and type 2 3beta-hydroxysteroid dehydrogenase and for the catalysis of the
type 1 activity, J. Biol. Chem. 277 (45) (2002) 42795–42801.
These kinetic analyses of the R195P-1 and P195R-2 mutant
3
-HSD enzymes support a key role for Arg195 that produces high-
[
[
affinity binding of human 3-HSD1 with the 17-hydroxyl group of
the competitive inhibitor, trilostane, and the 17-keto group of the
DHEA substrate. In contrast, the presence of Pro195 in 3-HSD2
apparently prevents this isoenzyme from binding these steroid
ligands with high-affinity and produces a shift in the inhibition
mode of trilostane to noncompetitive. It is especially noteworthy
that the proposed dual interaction of the guanidinium R-group of
Arg195 of the R195P-2 mutant of 3-HSD2 with the 16-hydroxy,
[
7] H. Jörnvall, B. Persson, M. Krook, S. Atrian, R. Gonzalez-Duarte, J. Jeffery, D.
Ghosh, Short-chain dehydrogenases/reductases (SDR), Biochemistry 34 (18)
(
1995) 6003–6013.
[8] J.L. Thomas, W.L. Duax, A. Addlagatta, L. Scaccia, K.A. Frizzell, S.B. Carloni, Ser-
ine 124 completes the Tyr, Lys and Ser triad responsible for the catalysis of
human type 1 3-hydroxysteroid dehydrogenase, J. Mol. Endocrinol. 33 (1)
1
7-keto groups of 16-hydroxy-DHEA substrate produces substan-
(
2004) 253–261.
tially higher affinity binding (12.2-fold lower Km values) for this
substrate compared to wild-type 3-HSD2. Exploiting these inter-
actions with Arg195 may produce highly selective inhibitors of
[9] V.Z. Pletnev, J.L. Thomas, F.L. Rhaney, L.S. Holt, L.A. Scaccia, T.C. Umland,
W.L. Duax, Rational proteomics V: structure-based mutagenesis has revealed
key residues responsible for substrate recognition and catalysis by the
dehydrogenase and isomerase activities in human 3-hydroxysteroid dehy-
drogenase/isomerase type 1, J. Steroid Biochem. Mol. Biol. 101 (1) (2006) 50–60.
[10] C. Filling, K.D. Berndt, J. Benach, T. Knapp, T. Prozorovski, E. Nordling, R.
Ladenstein, H. Jörnvall, U. Oppermann, Critical residues for structure and catal-
ysis in short chain dehydrogenases/reductases, J. Biol. Chem. 277 (28) (2002)
3
-HSD1 that may be effective as new treatments for hormone-
sensitive breast cancer.
The roles of other putative substrate and cofactor fingerprint
residues have been clarified. The Asp192 residue of 3-HSD appears
to interact with the 17-keto group of the DHEA substrate, and
kinetic analyses of the E192A mutant support a role for this residue
in substrate but not in cofactor utilization. In some members of
the short-chain dehydrogenase reductase family, Thr12 functions
with the NNAG (Asn-Asn-Ala-Gly) motif at residues 86–89 to bind
solvent (water) and mutation of that Thr (T12A) disrupts enzyme
function [10]. However, human 3-HSD lacks the NNAG motif [9].
Our kinetic analyses of the analogous Thr mutant, T8A, in human
25677–25684.
[11] J.L. Thomas, R. Huether, V.L. Mack, L.A. Scaccia, R.C. Stoner, W.L. Duax,
Structure/function of human type 1 3-hydroxysteroid dehydrogenase: an
intrasubunit disulfide bond in the Rossmann-fold domain and a Cys residue
in the active site are critical for substrate and coenzyme utilization, J. Steroid
Biochem. Mol. Biol. 107 (1–2) (2007) 80–87.
[
12] J.L. Thomas, V.L. Mack, J.A. Glow, D. Moshkelani, K.M. Bucholtz, Struc-
ture/function of the inhibition of human 3-hydroxysteroid dehydrogenase
type 1 and type 2 by trilostane, J. Steroid Biochem. Mol. Biol. 111 (1–2) (2008)
66–73.
[
13] J.B. Thoden, P.A. Frey, H.M. Holden, Crystal structures of the oxidized and
reduced forms of UDP-galactose 4-epimerase isolated from Escherichia coli,
Biochemistry 35 (16) (1996) 2557–2566.
3
-HSD1 show that Thr8 is not a critical residue in this enzyme.
The Arg61 residue in 3-HSD1 is analogous to Arg60 in bacte-
rial 3,17-hydroxysteroid dehydrogenase, which was shown by
mutagenesis to hydrogen bond with the 6-amino group on the ade-
nine of enzyme-bound NAD [10]. Our kinetic analyses with the
D61N mutant of 3-HSD1 suggest that Asp61 may play a similar
role in cofactor utilization in human 3-HSD1.
Understanding the structure/function relationships of the high-
affinity inhibition of 3-HSD1 by trilostane may lead to the
development of new, more specific inhibitors of 3-HSD1 that may
be used to block the production of estradiol from DHEA in breast
tumors without compromising steroidogenesis mediated by 3-
HSD2 in the human adrenal enzyme. Based on the success of the
aromatase inhibitors in treating hormone-sensitive breast tumors
[14] R. Shi, S.X. Lin, Cofactor hydrogen bonding onto the protein main chain is con-
served in the short chain dehydrogenase/reductase family and contributes to
nicotinamide orientation, J. Biol. Chem. 279 (16) (2004) 16778–16785.
[
15] J.D. Thompson, D.G. Higgins, T.J. Gibson, CLUSTAL W: improving the sensitiv-
ity of progressive multiple sequence alignment through sequence weighting,
position specific gap penalties and weight matrix choice, Nucl. Acids Res. 22
+
(
22) (1994) 4673–4680.
[
[
16] G.M Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, A.J.
Olson, Automated docking using a lamarckian genetic algorithm and empirical
binding free energy function, J. Comput. Chem. 19 (14) (1998) 1639–1662.
17] J.L. Thomas, B.W. Evans, G. Blanco, R.W. Mercer, J.I. Mason, S. Adler, W.E.
Nash, K.E. Isenberg, R.C. Strickler, Site-directed mutagenesis identifies amino
acid residues associated with the dehydrogenase and isomerase activities
of human type I (placental) 3-hydroxysteroid dehydrogenase/isomerase, J.
Steroid Biochem. Mol. Biol. 66 (5–6) (1998) 327–334.
[
[
18] M.M. Bradford, A rapid and sensitive method for the quantitation of micro-
gram quantities of protein utilizing the principle of protein-dye binding, Anal.
Biochem. 72 (May) (1976) 248–254.
19] J.L. Thomas, E.A. Berko, A. Faustino, R.P. Myers, R.C. Strickler, Human placen-
tal 3-hydroxy-5-ene-steroid dehydrogenase and steroid 5-4-ene-isomerase:
purification from microsomes, substrate kinetics, and inhibition by product
steroids, J. Steroid Biochem. 31 (5) (1988) 785–793.
[
25,26], the characterization of a new target enzyme in this biosyn-
thetic pathway enhances our ability to develop new treatments for
breast cancer.
[
20] I.H. Segel, Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium
and Steady-State Enzyme Systems, John Wiley & Sons, New York, 1993, pp.
Acknowledgments
109–111.
[
21] J.L. Thomas, W.L. Duax, A. Addlagatta, S. Brandt, R.R. Fuller, W. Norris,
Structure/function relationships responsible for coenzyme specificity and
This research was supported by NIH grant CA114717 (JLT).
We thank Gavin P. Vinson, DSc, PhD, School of Biological Sci-
ences, Queen Mary University of London, for the providing the
trilostane.
the isomerase activity of human type
1 3-hydroxysteroid dehydroge-
nase/isomerase, J. Biol. Chem. 278 (37) (2003) 35483–35490.
22] J.R. Pasqualini, The selective estrogen enzyme modulators in breast cancer: a
review, Biochim Biophys. Acta 1654 (2) (2004) 123–143.
[